ARIX BIOSCIENCE PLC Notice of Results and Investor Presentation
Transparency directive : regulatory news
|
Arix Bioscience PLC (ARIX)
Arix Bioscience plc
Notice of Results and Investor Presentation LONDON, 14 April 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, will announce its results for the full year ended 31 December 2022 on Thursday 20 April 2023. Analyst Briefing: 10:00am BST, Thursday 20 April 2023 Management will host a virtual briefing for Analysts at 10:00am BST on Thursday 20 April. Analysts wishing to join should register their interest by contacting Powerscourt on arix@powerscourt-group.com or on +44 (0) 20 7290 1050. Investor Presentation: 4:00pm BST, Thursday 20 April 2023 Management will be hosting a live presentation and Q&A session via the online platform, Investor Meet Company, at 4:00pm BST on Thursday 20 April 2023. The presentation is open to analysts and all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard or at any time during the live presentation via the "Ask a Question" function. Investors can sign up to Investor Meet Company for free via: https://www.investormeetcompany.com/arix-bioscience-plc/register-investor Investors who already follow Arix on the Investor Meet Company platform will automatically receive an invitation to the event.
[ENDS]
Enquiries For more information on Arix, please contact:
Arix Bioscience plc +44 (0)20 7290 1050
Powerscourt Group Sarah MacLeod, Ibrahim Khalil, Nick Johnson +44 (0)20 7250 1446
About Arix Bioscience plc Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. |
| ISIN: | GB00BD045071 |
| Category Code: | NOR |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 237071 |
| EQS News ID: | 1608089 |
| End of Announcement | EQS News Service |
|
|